Abstract
Several reports have provided evidence that body size early in life is positively correlated with risk of subsequent breast cancer, but the biological basis for this relationship is unclear. We examined tumour incidence in transgenic mice expressing a growth hormone (GH) antagonist and in non-transgenic littermates following exposure to dimethylbenz[ a ]anthracene (DMBA), a well characterized murine mammary gland carcinogen. The transgenic animals had lower IGF-I levels, were smaller in terms of body size and weight, and exhibited decreased tumour incidence relative to controls. The demonstration that both body size early in life and breast cancer incidence are influenced by experimental perturbation of the GH–IGF-I axis in a transgenic model provides evidence that variability between individuals with respect to these hormones underlies the relationship between body size early in life and breast cancer risk observed in epidemiological studies. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Barinaga M (1998) Study suggests new way to gauge prostate cancer risk. Science 279: 475
Bohlke K, Cramer DW, Trichopoulos D and Mantzoros CS (1998) Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9: 570–573
Bruning PF, Van DJ, Bonfrer JM, Van NP, Korse CM, Linders TC and Hart AA (1995) Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 62: 266–270
Burroughs KD, Dunn SE, Barrett JC and Taylor JE (1999) Insulin-like growth factor-I: a key regulator of human cancer risk?. J Natl Cancer Inst 91: 579–581
Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M and Hankinson SE (2000) Plasma insulin-like growth factor-I, insulin-like growth factor-binding protein-3 and mammographic density. Cancer Res 60: 3744–3748
Chan JM, Stampfer MK, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH and Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563–566
Chen WY, Wight DC, Wagner TE and Kopchick JJ (1990) Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci USA 87: 5061–5065
Chen WY, Wight DC, Mehta BV, Wagner TE and Kopchick JJ (1991) Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol Endocrinol 5: 1845–1852
Chen WY, Chen NY, Yum J, Washer TE and Kopchick JJ (1994) In vitro and in vivo studies of antagonistic effects of human growth hormone analogues. J Biol Chem 269: 15892–15897
Cohen SM and Ellwein LB (1990) Cell proliferation in carcinogenesis. Scienc 249: 1007–1011
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE and Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393–1396
Harrela M, Koinstinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, Toivanen L, Koskenvuo M, Leinonen P, Koistinene R and Seppala M (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J. Clin Invest 98: 2612–2615
Holly J and Smith GD (2000) Cancer and Insulin-like growth factor-I. BMJ 321: 847–848
Holly JM, Gunnell DJ and Smith GD (1999) Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer?. J Endo 162: 321–330
Jones JI and Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3–34
Kaijser M, Lichtenstein P, Granath F, Erlandsson G, Cnattingius S and Ekbom A (2001) In utero exposures and breast cancer: a study of opposite-sexed twins. J Natl Cancer Inst 93: 60–62
Khandwala HM, McCutcheon IE, Flyvbjerg A and Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21: 215–244
Li BD, Khosravi MJ, Berkel HJ, Diamandi A, Dayton MA, Smith M and Yu H (2001) Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 91: 736–739
Maison P, Balkau B, Simon D, Chanson P, Rosselin G and Eschwege E (1998) Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. BMJ 316: 1132–1133
Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, Adami HO and Mantzoros C (1999) IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 83: 15–17
Michels KB, Trichopoulos D, Robins JM, Rosner BA, Manson JE, Hunter DJ, Colditz GA, Hankinson SE, Speizer FE and Willett WC (1996) Birthweight as a risk factor for breast cancer. Lancet 348: 1542–1546
Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D and Bondy CA (1997) Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nature Medicine 3: 1141–1144
Ong K, Kratzsch J, Kiess W, Costello M, Scott C and Dunger D (2000) Size at birth and cord blood levels of insulin, insulin-like growth factor I (IGF-1), IGF-II, IGF-binding protein-1 (IGFBP-1), IGFBP-3, and the soluble IGF-II/mannose-6-phosphate receptor in term human infants. The ALSPAC Study team. Avon Longitudinal Study of Pregnancy and Childhood. J Clin Endocrinol Metab 85: 4266–4269
Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J and Demaille A (1993) Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A: 492–497
Pollak M (2000) Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36: 1224–1228
Pollak MN and Schally AV (1998) Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 217: 143–152
Pollak M, Beamer W and Zhang J-C (1999) Insulin-like growth factors and prostate cancer. Cancer and Metastases Reviews 17: 383–390
Rajaram S, Baylink DJ and Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endo Rev 18: 801–831
Russo J and Russo IH (1996) Experimentally induced mammary tumors in rats. Breast Cancer Research & Treatment 39: 7–20
Shaneyfelt T, Husein R, Bubley GJ and Mantzoros CS (2000) Hormonal Predictors of Prostate Cancer: A Meta-Analysis. J Clin Oncol 18: 847–853
Signorello LB and Trichopoulos D (1998) Perinatal determinants of adult cardiovascular disease and cancer. Scand J Soc Med 26: 161–165
Stavola BL, Hardy R, Kuh D, Silva IS, Wadsworth M and Swerdlow AJ (2000) Birthweight, childhood growth and risk of breast cancer in British cohort. Br J Cancer 83: 964–968
Stoll BA (1997) Birthweight as risk factor for breast cancer. Lancet 349: 501–502
Toniolo P, Brunning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Luknanova A, Short PA and Zeleniuch-Jacquotte A (2000) Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88: 828–832
Trainer PJ, Drake MB, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM and Scarlett JA (2000) Treatment of acromegaly with the growth hormone-receptor antagonist Pegvisomant. New Eng J Med 342: 1171–1177
United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) (1998) Guidelines for the Welfare of Animals in Experimental Neoplasion (Second Edition). Br J Cancer 77: 1–10
Vatten L (1996) Can prenatal factors influence future breast cancer risk?. Lancer 348: 1531–1531
Wolk A, Mantzoros CS, Andersson S-O, Bergstrom R, Signorello LB, Lagiou P, Adami H-O and Trichopoulos D (1998) Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90: 911–915
Wu X, Yu H, Amos CI, Hong WK and Spitz MR (2000) Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst 92: 737–743
Yu H, Spitz MR, Mistry J, Gu J, Hong WK and Wu X (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91: 151–156
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Pollak, M., Blouin, MJ., Zhang, JC. et al. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer 85, 428–430 (2001). https://doi.org/10.1054/bjoc.2001.1895
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1895
Keywords
This article is cited by
-
Extending lifespan by modulating the growth hormone/insulin-like growth factor-1 axis: coming of age
Pituitary (2021)
-
Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies
Investigational New Drugs (2015)
-
Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia
Breast Cancer Research and Treatment (2015)
-
The GH/IGF-1 axis in ageing and longevity
Nature Reviews Endocrinology (2013)